Noninvasive cardiac testing in the end-stage renal disease patient

Richard A. Wilson, Douglas Norman, John Barry, William M. Bennett

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Renal transplant candidates are at increased risk for future cardiac death - approximately 5-10% per year. Invasive testing by coronary angiography has been used to assess the cardiac risk. However this is expensive and carries its own risks to residual renal function as well as cardiac morbidity and mortality. Screening of patients by clinical risk factors may obviate the need for invasive or noninvasive testing in a significant number (approximately 50%) of the renal transplant candidates. Further noninvasive testing with exercise or dipyridamole thallium-201 stress testing in the high-risk patients may be a more cost-effective screening test than coronary angiography. Other noninvasive testing modalities may also prove useful in the future but have not yet been proven in this unique patient population. The characterization of a renal transplant candidate’s cardiac risk may assist the clinicians in prioritizing the candidate for transplantation. Recent evidence also suggests that revascularization of the diabetic renal transplant candidate with significant coronary artery disease (which is approachable by angioplasty or bypass surgery) may modify their cardiac risk. Randomized studies of the efficacy of revascularization or medical therapy interventions in the nondiabetic renal transplant candidate with coronary artery disease have not been performed.

Original languageEnglish (US)
Pages (from-to)78-83
Number of pages6
JournalBlood Purification
Volume12
Issue number1
DOIs
StatePublished - 1994

Fingerprint

Chronic Kidney Failure
Kidney
Transplants
Coronary Angiography
Coronary Artery Disease
Dipyridamole
Thallium
Angioplasty
Transplantation
Exercise
Morbidity
Costs and Cost Analysis
Mortality
Population

Keywords

  • Cardiac catheterization
  • Cardiac mortality
  • Diabetes
  • Noninvasive cardiac testing
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Cite this

Noninvasive cardiac testing in the end-stage renal disease patient. / Wilson, Richard A.; Norman, Douglas; Barry, John; Bennett, William M.

In: Blood Purification, Vol. 12, No. 1, 1994, p. 78-83.

Research output: Contribution to journalArticle

Wilson, Richard A. ; Norman, Douglas ; Barry, John ; Bennett, William M. / Noninvasive cardiac testing in the end-stage renal disease patient. In: Blood Purification. 1994 ; Vol. 12, No. 1. pp. 78-83.
@article{6400781ef9ad40328b07b43594ff03f3,
title = "Noninvasive cardiac testing in the end-stage renal disease patient",
abstract = "Renal transplant candidates are at increased risk for future cardiac death - approximately 5-10{\%} per year. Invasive testing by coronary angiography has been used to assess the cardiac risk. However this is expensive and carries its own risks to residual renal function as well as cardiac morbidity and mortality. Screening of patients by clinical risk factors may obviate the need for invasive or noninvasive testing in a significant number (approximately 50{\%}) of the renal transplant candidates. Further noninvasive testing with exercise or dipyridamole thallium-201 stress testing in the high-risk patients may be a more cost-effective screening test than coronary angiography. Other noninvasive testing modalities may also prove useful in the future but have not yet been proven in this unique patient population. The characterization of a renal transplant candidate’s cardiac risk may assist the clinicians in prioritizing the candidate for transplantation. Recent evidence also suggests that revascularization of the diabetic renal transplant candidate with significant coronary artery disease (which is approachable by angioplasty or bypass surgery) may modify their cardiac risk. Randomized studies of the efficacy of revascularization or medical therapy interventions in the nondiabetic renal transplant candidate with coronary artery disease have not been performed.",
keywords = "Cardiac catheterization, Cardiac mortality, Diabetes, Noninvasive cardiac testing, Transplantation",
author = "Wilson, {Richard A.} and Douglas Norman and John Barry and Bennett, {William M.}",
year = "1994",
doi = "10.1159/000170149",
language = "English (US)",
volume = "12",
pages = "78--83",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Noninvasive cardiac testing in the end-stage renal disease patient

AU - Wilson, Richard A.

AU - Norman, Douglas

AU - Barry, John

AU - Bennett, William M.

PY - 1994

Y1 - 1994

N2 - Renal transplant candidates are at increased risk for future cardiac death - approximately 5-10% per year. Invasive testing by coronary angiography has been used to assess the cardiac risk. However this is expensive and carries its own risks to residual renal function as well as cardiac morbidity and mortality. Screening of patients by clinical risk factors may obviate the need for invasive or noninvasive testing in a significant number (approximately 50%) of the renal transplant candidates. Further noninvasive testing with exercise or dipyridamole thallium-201 stress testing in the high-risk patients may be a more cost-effective screening test than coronary angiography. Other noninvasive testing modalities may also prove useful in the future but have not yet been proven in this unique patient population. The characterization of a renal transplant candidate’s cardiac risk may assist the clinicians in prioritizing the candidate for transplantation. Recent evidence also suggests that revascularization of the diabetic renal transplant candidate with significant coronary artery disease (which is approachable by angioplasty or bypass surgery) may modify their cardiac risk. Randomized studies of the efficacy of revascularization or medical therapy interventions in the nondiabetic renal transplant candidate with coronary artery disease have not been performed.

AB - Renal transplant candidates are at increased risk for future cardiac death - approximately 5-10% per year. Invasive testing by coronary angiography has been used to assess the cardiac risk. However this is expensive and carries its own risks to residual renal function as well as cardiac morbidity and mortality. Screening of patients by clinical risk factors may obviate the need for invasive or noninvasive testing in a significant number (approximately 50%) of the renal transplant candidates. Further noninvasive testing with exercise or dipyridamole thallium-201 stress testing in the high-risk patients may be a more cost-effective screening test than coronary angiography. Other noninvasive testing modalities may also prove useful in the future but have not yet been proven in this unique patient population. The characterization of a renal transplant candidate’s cardiac risk may assist the clinicians in prioritizing the candidate for transplantation. Recent evidence also suggests that revascularization of the diabetic renal transplant candidate with significant coronary artery disease (which is approachable by angioplasty or bypass surgery) may modify their cardiac risk. Randomized studies of the efficacy of revascularization or medical therapy interventions in the nondiabetic renal transplant candidate with coronary artery disease have not been performed.

KW - Cardiac catheterization

KW - Cardiac mortality

KW - Diabetes

KW - Noninvasive cardiac testing

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0028021605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028021605&partnerID=8YFLogxK

U2 - 10.1159/000170149

DO - 10.1159/000170149

M3 - Article

C2 - 7986481

AN - SCOPUS:0028021605

VL - 12

SP - 78

EP - 83

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 1

ER -